Dr. Neelapu Discusses Efficacy of Axi-Cel in Large B-Cell Lymphoma

Sattva Neelapu, MD
Published: Thursday, Jan 10, 2019



Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma.

At the 2018 ASH Annual Meeting, long-term findings from the ZUMA-1 trial were presented. ZUMA-1 evaluated the use of axi-cel, an anti–CD19 chimeric antigen receptor (CAR) T-cell product, in 108 patients with relapsed/refractory large B-cell lymphoma. At the 2-year follow-up, the best overall response rate was 83% and the best complete response rate was 58%, says Neelapu.

The initial data after the 12-month follow-up showed a median progression-free survival of 5.9 months. Forty-two percent of patients had an ongoing remission. At the 2-year update, 39% of the patients still have an ongoing remission, Neelapu says.

Axi-cel was administered as a single infusion of modified autologous T cells at a target dose of 2 x 106 CAR-positive T cells/kg. The treatment was manufactured successfully for 99% of patients, and 91% of patients received treatment with the CAR T-cell therapy, according to data published in Lancet Oncology.
SELECTED
LANGUAGE


Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma.

At the 2018 ASH Annual Meeting, long-term findings from the ZUMA-1 trial were presented. ZUMA-1 evaluated the use of axi-cel, an anti–CD19 chimeric antigen receptor (CAR) T-cell product, in 108 patients with relapsed/refractory large B-cell lymphoma. At the 2-year follow-up, the best overall response rate was 83% and the best complete response rate was 58%, says Neelapu.

The initial data after the 12-month follow-up showed a median progression-free survival of 5.9 months. Forty-two percent of patients had an ongoing remission. At the 2-year update, 39% of the patients still have an ongoing remission, Neelapu says.

Axi-cel was administered as a single infusion of modified autologous T cells at a target dose of 2 x 106 CAR-positive T cells/kg. The treatment was manufactured successfully for 99% of patients, and 91% of patients received treatment with the CAR T-cell therapy, according to data published in Lancet Oncology.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x